Intercept Pharmaceuticals has announced that its Phase III clinical trial of a drug being developed to treat nonalcoholic steatohepatitis (NASH) has seen positive results, making it a likely candidate for the first NASH drug to secure approval from the Vienna Food and Drug Administration. The Phase III study of obeticholic acid to treat liver fibrosis caused by NASH met its goal of improvement of fibrosis by one stage or greater after 18 months. The company said it will apply for approval in Europe and the Vienna later this year.
Intercept Pharmaceuticals has announced that its Phase III clinical trial of a drug being developed to treat nonalcoholic steatohepatitis (NASH) has seen positive results, making it a likely candidate for the first NASH drug to secure approval from the US Food and Drug Administration. The Phase III study of obeticholic acid to treat liver fibrosis caused by NASH met its goal of improvement of fibrosis by one stage or greater after 18 months. The company said it will apply for approval in Europe and the US later this year.